Downloads
Geiger K, Joerger M, Roessler M, Hettwer K, Ritter C, Simon K, Uhlig S, Holdenrieder S.
Relevance of tumor markers for prognosis, prediction and monitoring of therapy response in non-small cell lung cancer patients – a CEPAC-TDM biomarker substudy.
Schroeder L, Mallmann M, Domroese C, Wefers N, Dolscheid-Pommerich R, Stoffel-Wagner B, Trulson I, Vahldiek K, Klawonn F, Holdenrieder S.
Method comparison and clinical performance of breast cancer tumor markers on novel multiplex immunoassay and automatized LOCI technology platforms.
Dorman K, Gehrkens M, Kruger S, Krueger K, Mayer Z, Rupp A, Zhang D, Weiss L, Westphalen CB, Haas M, Guenther M, Ormanns S, Klawonn F, Werner J, von Bergwelt-Baildon M, Heinemann V, Boeck S, Holdenrieder S.
Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers.
Schroeder L, Domroese C, Rupp AB, Gihr KME, Niederau C, Mallmann M, Holdenrieder S.
Clinical application of tissue polypeptide antigen and CA 125 in gynaecologic malignancie
Schroeder L, Rupp AB, Gihr KME, Kobilay M, Domroese C, Mallmann M, Holdenrieder S.
Immunogenic biomarkers HMGB1 and sRAGE are potential diagnostic tools for ovarian malignancies.
Dohmen J, Semaan A, Kobilay M, Zaleski M, Branchi V, Schlierf A, Hettwer K, Uhlig S, Hartmann G, Kalff JC, Matthaei H, Lingohr P, Holdenrieder S.
Dutsch A, Uhlig C, Bock M, Graesser C, Schuchardt S, Uhlig S, Schunkert H, Joner M, Holdenrieder S, Lechner K. Multi-omic candidate screening for markers of severe clinical courses of COVID-19
Geiger K, Joerger M, Roessler M, Hettwer K, Ritter C, Simon K, Uhlig S, Holdenrieder S.
Relevance of tumor markers for prognosis, prediction and monitoring of therapy response in non-small cell lung cancer patients – a CEPAC-TDM biomarker substudy.
Schroeder L, Mallmann M, Domroese C, Wefers N, Dolscheid-Pommerich R, Stoffel-Wagner B, Trulson I, Vahldiek K, Klawonn F, Holdenrieder S.
Method comparison and clinical performance of breast cancer tumor markers on novel multiplex immunoassay and automatized LOCI technology platforms.
Dorman K, Gehrkens M, Kruger S, Krueger K, Mayer Z, Rupp A, Zhang D, Weiss L, Westphalen CB, Haas M, Guenther M, Ormanns S, Klawonn F, Werner J, von Bergwelt-Baildon M, Heinemann V, Boeck S, Holdenrieder S.
Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IFN-γ, TNF-α and PD-1/PD-L1 in comparison to established serum tumor markers.
Schroeder L, Domroese C, Rupp AB, Gihr KME, Niederau C, Mallmann M, Holdenrieder S.
Clinical application of tissue polypeptide antigen and CA 125 in gynaecologic malignancie
Schroeder L, Rupp AB, Gihr KME, Kobilay M, Domroese C, Mallmann M, Holdenrieder S.
Immunogenic biomarkers HMGB1 and sRAGE are potential diagnostic tools for ovarian malignancies.
Dohmen J, Semaan A, Kobilay M, Zaleski M, Branchi V, Schlierf A, Hettwer K, Uhlig S, Hartmann G, Kalff JC, Matthaei H, Lingohr P, Holdenrieder S.
Dutsch A, Uhlig C, Bock M, Graesser C, Schuchardt S, Uhlig S, Schunkert H, Joner M, Holdenrieder S, Lechner K. Multi-omic candidate screening for markers of severe clinical courses of COVID-19
